Summary
Previous research has shown that patients with Myocardial Infarction (MI) experience decreased health related quality of life (HRQoL) compared to the general population (Lewis et al. 2014; Schweikert et al. 2008).
Full descriptionThe American Heart Association recommends the inclusion of patient’s HRQoL as an important measure of cardiovascular health among patients with cardiovascular disease (Rumsfeld et al. 2013). Medication adherence is necessary for effective therapy and there is evidence to suggest insufficient observed and self-reported adherence to medications (Krack et al. 2018). To improve adherence, its determinants need to be known.
There are a few studies that have looked at the associations between medication adherence, patient satisfaction with medicines, and patient health related quality of life using longitudinal data. Therefore the aim of this project is to investigate associations of HRQoL, patient satisfaction with medicines, and medication adherence among AMI patients. We hypothesize that decreased HRQoL is associated with decreased medication adherence.
Data sources:
The project will use EMMACE 3 and 4 data. EMMACE-3 is a national, multi-centre, prospective, longitudinal cohort of patients hospitalised with Acute Coronary Syndrome (ACS) in England. 5556 patients were recruited between 1st November, 2011 and 17th September, 2013. Patient reported data at admission, 1 month, 6 months and 1 year follow-up comprised: Morisky Medication Adherence, Single Question Medicine Adherence, and Beliefs about Medicine, The Adherence Estimator and Problems with Taking medications, Satisfaction with Information about Medicines Scale, and EQ-5D. All patients were consented to enter the study and for their data to be linked to electronic health record data.
EMMACE-4 is also a national, multi-centre, prospective, longitudinal cohort of patients hospitalised with ACS in England. 9343 patients were recruited between October 2013 to 24th June 2015. Patient reported outcome measures data at admission, 1 month, 6 months and 1 year follow-up comprised of Satisfaction with Information about Medicines Scale, List of Medications, Care Quality Commission Pickering Inpatient PROM, Brief Illness Perception, and EQ-5D.
References:
KRACK, G., R. HOLLE, I. KIRCHBERGER, B. KUCH, U. AMANN and H. SEIDL. 2018. Determinants of adherence and effects on health-related quality of life after myocardial infarction: a prospective cohort study. BMC geriatrics, 18(1), p136.
LEWIS, E. F., Y. LI, M. A. PFEFFER, S. D. SOLOMON, K. P. WEINFURT, E. J. VELAZQUEZ, R. M. CALIFF, J.-L. ROULEAU, L. KOBER and H. D. WHITE. 2014. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC: Heart Failure, 2(2), pp.159-165.
RUMSFELD, J. S., K. P. ALEXANDER, D. C. GOFF JR, M. M. GRAHAM, P. M. HO, F. A. MASOUDI, D. K. MOSER, V. L. ROGER, M. S. SLAUGHTER and K. G. SMOLDEREN. 2013. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation, 127(22), pp.2233-2249.
SCHWEIKERT, B., M. HUNGER, C. MEISINGER, H.-H. KÖNIG, O. GAPP and R. HOLLE. 2008. Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general population. European heart journal, 30(4), pp.436-443.
